Many 340B Disproportionate Share Hospitals Fail to Reinvest in Patient Care
A new analysis of 340B hospital data found that the number of Disproportionate Share Hospitals (DSHs) participating in the 340B Drug Pricing Program1 has surged more than sixfold, rising 565% from 2004 to 2023, with little evidence of commensurate growth in benefit to vulnerable populations. Yet, following 340B enrollment, DSHs’ financial investments, including stocks, bonds and other financial instruments, soared.
